Creatine Monohydrate
Creatine Monohydrate scored 8.1 / 10 (✅ Top-tier) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
What It Is
Creatine monohydrate is a naturally occurring compound (synthesized from arginine, glycine, and methionine) that replenishes phosphocreatine stores in muscle and brain tissue, serving as a rapid ATP regeneration buffer during high-intensity work. It is the single most researched sports supplement in history, with 680+ trials spanning 30+ years and 12,800+ participants. Type: Vitamin / Mineral / Nutrient (endogenous metabolite) Current status: FDA GRAS (GRN-931, 2020). EFSA-approved health claims at 3g/day. Available OTC worldwide. No regulatory concerns.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 1 route and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| oral | powder (monohydrate) | 3-5g/day ISSN position stand; 500+ RCTs at this range | 3-5g/day Universal community consensus; no benefit above 5g/day maintenance |
Protocols
Standard maintenance Clinical
- Dose
- 3-5g/day oral
- Frequency
- daily
- Duration
- indefinite
Well-tolerated; muscle saturation in 3-4 weeks without loading. ISSN recommended.
Loading protocol Clinical
- Dose
- 20g/day (4x5g split doses) for 5-7 days, then 3-5g/day
- Frequency
- daily
- Duration
- loading 5-7d then indefinite maintenance
Saturates stores in 5-7 days vs 3-4 weeks. Higher GI side effect rate at 10g+ single doses. Declining popularity in community (~30% use it).
Low-dose cognitive Mixed
- Dose
- 2-3g/day oral
- Frequency
- daily
- Duration
- indefinite
Minimum effective dose; favored by nootropic community for brain benefits without water retention.
High-dose cognitive (research) Clinical
- Dose
- 10-20g/day oral
- Frequency
- daily
- Duration
- 4-6 weeks
Used in TBI and depression research. Higher GI risk. Not standard practice.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
| Cognition Focus | 5g/day standard; researchers have used 10-20g/day for cognitive endpoints | Stronger effects in vegetarians, females, sleep-deprived, and ages 18-60 |
| Depression | 6g/day | Toniolo RCT in bipolar depression; 66.7% vs 18.2% remission |
| Geriatric | 3-5g/day with resistance training | Muscle, bone, and cognitive benefits in older adults |
| Strength Power | 5g/day; optional loading | SMD 0.43 overall; loading provides faster saturation but not greater long-term effect |
How this score is calculated →
Upside (3.33 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.8 | 1.200 | |
| Breadth of Benefits | 15% | 4.5 | 0.675 | |
| Evidence Quality | 25% | 4.5 | 1.125 | |
| Speed of Onset | 10% | 3.5 | 0.350 | |
| Durability | 10% | 4.5 | 0.450 | |
| Bioindividuality Upside | 15% | 3.5 | 0.525 | |
| Total | 4.325 |
Upside Rationale
Efficacy (4.8/5.0) Creatine is one of the most effective supplements ever studied. Strength gains show SMD 0.43 overall across 14 RCTs (n=523), rising to SMD 1.06 in untrained individuals. Lean mass increases average +1.10 kg with resistance training and +1.37 kg in older adults. Beyond muscle, the 2024 pooled cognitive meta-analysis (16 RCTs, n=492) shows memory improvements at g=0.30, with stronger effects in females, diseased populations, and those aged 18-60. A bipolar depression RCT showed 66.7% vs 18.2% remission at 6g/day.
Breadth of Benefits (4.5/5.0) Creatine affects multiple biological systems: muscular (strength, hypertrophy, power), neurological (cognition, memory, neuroprotection, TBI), skeletal (bone density in older adults), metabolic (methylation sparing via SAM cycle, glucose disposal), and psychiatric (depression augmentation). Few supplements span this breadth with evidence backing each domain.
Evidence Quality (4.5/5.0) The most extensively studied supplement in history. 680+ trials, 500+ RCTs, 20+ meta-analyses, multiple independent replications across labs worldwide. Cochrane-quality systematic reviews exist. Independent replication is robust. Industry funding exists but findings are consistently replicated by independent groups. The 2017 ISSN position stand references 500+ studies.
Speed of Onset (3.5/5.0) Performance benefits emerge within 5-7 days with loading (20g/day) or 3-4 weeks with standard dosing (3-5g/day). Cognitive benefits require longer saturation (2-4 weeks minimum). Acute effects on high-intensity repeated bouts can be measured within days of full saturation.
Durability (4.5/5.0) Benefits are maintained with continued supplementation. Phosphocreatine stores take 4-6 weeks to return to baseline after cessation (up to 8 weeks in high-muscle-mass individuals). At 30 days post-cessation, stores remain ~20-25% above baseline. Not permanent, but highly durable with ongoing use.
Bioindividuality Upside (3.5/5.0) ~70-80% of people are clear responders. Vegetarians and vegans show amplified responses (lower baseline stores). Females show stronger cognitive effects. Older adults show enhanced muscle and bone responses. ~20-30% are non-responders, typically those with already-saturated baseline stores (heavy meat eaters, high type II fiber proportion). Key genes: SLC6A8 (transporter), ACTN3, GAMT/AGAT.
Downside (0.32 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.5 | 0.450 | |
| Side Effect Profile | 15% | 1.5 | 0.225 | |
| Financial Cost | 5% | 1.0 | 0.050 | |
| Time/Effort Burden | 5% | 1.0 | 0.050 | |
| Opportunity Cost | 5% | 1.0 | 0.050 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.225 | |||
| Harm subtotal × 1.4 | 1.505 | |||
| Opportunity subtotal × 1.0 | 0.150 | |||
| Combined downside | 1.655 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.315 |
Downside Rationale
Safety Risk (1.5/5.0) Among the safest supplements ever studied. The 2025 systematic review (680+ trials, 12,800+ participants) found no serious adverse events attributable to creatine. Side effect incidence in creatine groups (13.7%) is statistically indistinguishable from placebo (13.2%). The "kidney damage" myth is comprehensively debunked: 2025 BMC Nephrology meta-analysis (21 studies) confirms GFR is unaffected. Creatinine elevation is a benign metabolic byproduct, not renal impairment. No deaths, no organ damage, no permanent injuries across 50+ years of research. Catastrophic risk floor NOT triggered.
Side Effect Profile (1.5/5.0) GI symptoms (bloating, cramping, diarrhea) are the primary concern and are dose-dependent. At 3-5g/day, GI side effects equal placebo. Single doses >10g double diarrhea incidence (55.6% vs 28.6%). Water retention: 1-3 kg during loading, 0.5-1.5 kg at maintenance, fully reversible in 4-6 weeks. Hair loss/DHT concern definitively debunked by 2025 12-week RCT showing no DHT changes.
Financial Cost (1.0/5.0) Among the cheapest effective supplements. $0.10-0.20/day for 5g monohydrate. USP/NSF-certified options available under $0.30/day. No premium forms needed; monohydrate outperforms or equals all alternatives in head-to-head RCTs.
Time/Effort Burden (1.0/5.0) One scoop of powder mixed in any liquid, once daily. Under 30 seconds of preparation. No timing precision required (consistency matters more than pre/post workout).
Opportunity Cost (1.0/5.0) Complements virtually every other supplement and protocol. No meaningful interactions. Stacks well with protein, beta-alanine, caffeine, and resistance training. Does not crowd out alternatives.
Dependency/Withdrawal (1.0/5.0) No tolerance, no adaptation, no withdrawal, no rebound. Phosphocreatine stores simply return to baseline over 4-6 weeks after cessation. No physiological dependency mechanism exists.
Reversibility (1.0/5.0) Fully reversible on cessation. All effects (performance, cognitive, weight gain) normalize within 4-8 weeks. No permanent changes. Among the most reversible interventions scored.
Verdict
✅ Best for: Athletes and strength trainers seeking reliable performance gains. Cognitive workers, especially vegetarians/vegans (amplified brain creatine response). Older adults for muscle preservation, bone density, and cognitive support. Anyone looking for the single highest evidence-to-cost ratio supplement available. Depression augmentation (emerging, discuss with provider).
❌ Avoid if: Pre-existing chronic kidney disease (CKD stages 3-5, insufficient safety data in this population). McArdle disease (Cochrane-confirmed contraindication). If making weight for a sport where 1-3 lbs of water retention matters (competition cutting phase). If your doctor misinterprets elevated creatinine as kidney damage, request cystatin C-based GFR measurement instead.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ✅ Strength / Power | 8.5 | Most robust endpoint: SMD 0.43 overall (14 RCTs, n=523), 1.06 in untrained; 500+ RCTs |
| ✅ Muscle Growth / Hypertrophy | 8.0 | +1.10 kg lean mass with resistance training; +1.37 kg in older adults; cell volumization signal |
| 💪 Geriatric / Aging Population | 7.5 | Strong evidence for muscle, cognition, and bone density in older adults; amplified response in aging populations |
| 💪 Memory | 7.0 | Strongest cognitive endpoint in pooled analysis; short-term memory and processing speed; vegetarians show amplified response |
| 💪 Recovery / Repair | 7.0 | Phosphocreatine replenishment; reduces DOMS and muscle damage markers; accelerates return to training |
| 💪 Energy / Fatigue | 7.0 | Core mechanism: rapid ATP regeneration buffer via phosphocreatine system; both muscle and brain energy |
| 👍 Cognition / Focus | 6.5 | 2024 meta-analysis (16 RCTs, n=492): memory g=0.30; stronger in females, stressed, and sleep-deprived (PMID 39070254) |
| 👍 Neuroprotection | 6.0 | Brain energy buffer; strong animal TBI data; emerging human evidence for neuroprotective effects |
| 👍 Body Composition / Fat Loss | 6.0 | +1.10 kg lean mass with RT; indirect fat loss via increased metabolic activity and training capacity |
| 👍 Healthspan | 6.0 | Multiple converging pathways in aging: muscle preservation, cognitive support, bone density, methylation |
| ⚖️ Bone / Joint Health | 5.5 | Evidence for bone mineral density improvement in older adults when combined with resistance training |
| ⚖️ Depression | 5.5 | 66.7% vs 18.2% remission in bipolar depression at 6g/day (single RCT); augmentation potential |
| ⚖️ Methylation Support | 5.5 | Well-established SAM cycle sparing mechanism; reduces endogenous creatine synthesis burden, freeing methyl groups |
| ⚖️ Injury Recovery | 5.5 | Helps maintain muscle mass during immobilization; accelerates return to training post-injury |
| ⚖️ Traumatic Brain Injury | 5.5 | Promising animal data for brain energy buffering post-TBI; one human pilot; mechanism is compelling |
| ⚖️ Mitochondrial | 5.0 | ATP buffer supports mitochondrial energy output; phosphocreatine shuttle between mitochondria and cytoplasm |
| ⚖️ Mood / Emotional Regulation | 5.0 | Bipolar depression remission data (Toniolo RCT); general mood support via brain energy |
| ⚖️ Stress / Resilience | 5.0 | Cognitive performance maintained under sleep deprivation and acute stress; brain PCr buffering |
| ○ Metabolic Health | 4.5 | Some evidence for GLUT4 translocation and glucose disposal with exercise; methylation support |
| ○ Endurance / Cardio | 4.5 | Benefits repeated sprint ability and high-intensity intervals; limited steady-state endurance benefit |
| ○ Longevity / Lifespan | 4.5 | Methylation sparing, neuroprotection, muscle maintenance; no direct lifespan data in humans |
| ○ Cardiovascular | 4.0 | Homocysteine reduction via methylation sparing; some evidence for vascular function |
| ○ Neuroplasticity | 4.0 | Brain energy support for plasticity processes; theoretical mechanism, limited direct evidence |
| ○ Reaction Time / Coordination | 4.0 | Some evidence for improved reaction time under fatigue and sleep deprivation |
| ○ Blood Sugar / Glycemic Control | 3.5 | Emerging evidence for improved glycemic control when combined with exercise |
| ○ Flow State / Peak Mental Performance | 3.5 | Brain energy buffer during demanding cognitive tasks; theoretical support only |
| ○ Anti-Inflammatory | 3.5 | Some evidence for reducing CRP and inflammatory markers post-exercise |
| ○ Fertility (Male) | 3.5 | Some evidence for improved sperm motility; limited studies |
| ○ Anxiety | 3.0 | Very limited direct evidence; theoretical via brain energy under stress |
| ○ Sleep Quality | 3.0 | May reduce sleep need via brain energy; minimal direct evidence; some community reports of vivid dreams |
| ○ Nerve Regeneration | 3.0 | Neuroprotective mechanism plausible; no direct nerve regeneration studies |
| ○ VO2 Max | 3.0 | Minor indirect benefit via anaerobic threshold; not a primary VO2max intervention |
| ○ Antioxidant / Oxidative Stress | 3.0 | Indirect reduction in oxidative stress markers; not a primary antioxidant |
| ○ Chronic Pain Management | 3.0 | Some evidence in fibromyalgia; very limited |
| ○ Pregnancy Safety | 3.0 | Animal studies show safety; human RCTs underway (recruiting); insufficient data for recommendation |
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension changes | New score |
|---|---|---|
| Large RCT confirms cognitive effects in healthy adults with d>0.5 | Efficacy 4.8→5.0, Breadth 4.5→4.7 | 8.4 / 10 ✅ Top-tier |
| Long-term (10+ year) prospective study shows unexpected renal effect | Safety 1.5→2.5, Evidence 4.5→4.3 | 7.6 / 10 💪 Strong recommend |
| Phase 3 TBI trial shows significant neuroprotection | Breadth 4.5→4.8, Evidence 4.5→4.7 | 8.5 / 10 ✅ Top-tier |
| Meta-analysis downgrades cognitive effect sizes to d<0.1 | Efficacy 4.8→4.5, Breadth 4.5→4.2 | 7.7 / 10 💪 Strong recommend |
Key Evidence Sources
- Kreider RB et al. ISSN Position Stand: Creatine Supplementation. JISSN 2017 — Definitive position paper; 500+ references
- Forbes SC et al. Meta-analysis: creatine and cognition. Exp Gerontol 2024 — First pooled meta (16 RCTs, n=492); memory g=0.30
- Lanhers C et al. Creatine and upper body strength: systematic review. Eur J Sport Sci 2017 — SMD 0.43 (14 RCTs); untrained SMD 1.06
- Toniolo RA et al. Creatine augmentation in bipolar depression RCT. Acta Psychiatr Scand 2018 — 66.7% vs 18.2% remission at 6g/day
- Candow DG et al. Creatine and bone health: systematic review. 2023 — Bone density improvements in older adults with RT
- Kreider RB et al. Creatine in health and disease. Nutrients 2021 — Comprehensive review of safety and therapeutic applications
- Dolan E et al. Beyond muscle: brain creatine homeostasis. Exp Physiol 2019 — Brain creatine as therapeutic target
- Antonio J et al. Systematic review: creatine safety across all populations. JISSN 2025 — 680+ trials, 12,800+ participants; side effect rate equals placebo at 3-5g/day
- Ostojic SM. BMC Nephrology meta-analysis: creatine and kidney function. 2025 — 21 studies; GFR unaffected; creatinine elevation is benign metabolic marker
- Candow DG et al. Hair loss and DHT RCT. JISSN 2025 — 12-week RCT; no DHT changes; debunks hair loss concern
- Roschel H et al. Creatine in exercise, sport, and medicine. JISSN 2021 — Updated review of mechanisms and clinical applications
- Avgerinos KI et al. Effects of creatine on cognition. Exp Gerontol 2018 — Earlier cognitive meta-analysis; positive for memory
- Rawson ES et al. Creatine and brain health. Nutrients 2018 — TBI, depression, and neuroprotection evidence
- Branch JD. Effect of creatine on body composition. Int J Sport Nutr 2003 — +1.10 kg lean mass with RT
- Chilibeck PD et al. Creatine in older adults: meta-analysis. Med Sci Sports Exerc 2017 — +1.37 kg lean mass in older adults with RT
Other interventions for Cognition / Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.330 − 0.320 = 3.010
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((3.010 + 7) / 12) × 10 = 8.1 / 10
